Search Results - "Páramo, Dolores"

Skin Autoimmunity Secondary to Alemtuzumab in a Tertiary Care Spanish Hospital by López Ruiz, Rocío, Sánchez Fernández, Félix, Ruiz de Arcos, María, Dotor García-Soto, Julio, Fuerte Hortigón, Alejandro, Navarro Mascarell, Guillermo, Ruiz Peña, Juan Luis, Páramo Camino, M. Dolores, Guerra Hiraldo, Juan Diego, Eichau, Sara

“…The most common adverse events (AEs) after alemtuzumab (ALZ) include adverse infusion reactions, infections, and autoimmune disorders. Skin AEs are common…”
Get full text

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study by Izquierdo, Guillermo, Damas, Fátima, Páramo, Maria Dolores, Ruiz-Peña, Juan Luis, Navarro, Guillermo

“…Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstrated the efficacy and safety of fingolimod in patients with…”
Get full text

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients by Vázquez-Marrufo, Manuel, Galvao-Carmona, Alejandro, Caballero-Díaz, Rocio, Borges, Monica, Paramo, Maria Dolores, Benítez-Lugo, Maria Luisa, Ruiz-Peña, Juan Luis, Izquierdo, Guillermo

“…Functional neuroanatomy of cognitive impairment in multiple sclerosis is currently still a challenge. During the progression of the disease, several cognitive…”
Get full text

Disentangling the attention network test: behavioral, event related potentials, and neural source analyses by Galvao-Carmona, Alejandro, González-Rosa, Javier J, Hidalgo-Muñoz, Antonio R, Páramo, Dolores, Benítez, María L, Izquierdo, Guillermo, Vázquez-Marrufo, Manuel

“…The study of the attentional system remains a challenge for current neuroscience. The "Attention Network Test" (ANT) was designed to study simultaneously three…”
Get full text

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study by Fernández, Oscar, Izquierdo, Guillermo, Fernández, Victoria, Leyva, Laura, Reyes, Virginia, Guerrero, Miguel, León, Antonio, Arnaiz, Carlos, Navarro, Guillermo, Páramo, Maria Dolores, Cuesta, Antonio De la, Soria, Bernat, Hmadcha, Abdelkrim, Pozo, David, Fernandez-Montesinos, Rafael, Leal, Maria, Ochotorena, Itziar, Gálvez, Patricia, Geniz, Maria Angeles, Barón, Francisco Javier, Mata, Rosario, Medina, Cristina, Caparrós-Escudero, Carlos, Cardesa, Ana, Cuende, Natividad

“…Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal derived…”
Get full text

Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports by Fuerte-Hortigón, A, López Ruiz, R, Hiraldo, JDG, Sánchez Fernández, F, Dotor García-Soto, J, Páramo, María Dolores, Ruiz-Peña, JL, Navarro-Mascarell, G, Eichau, S

“…•Teriflunomide is an oral first-line therapy used in relapsing forms of MS.•The washout period of teriflunomide may be accelerated by cholestyramine.•Clearance…”
Get full text

Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders by Guasp, Mar, Rosa-Justicia, Mireia, Muñoz-Lopetegi, Amaia, Martínez-Hernández, Eugenia, Armangué, Thais, Sugranyes, Gisela, Stein, Heike, Borràs, Roger, Prades, Laia, Ariño, Helena, Planagumà, Jesús, De-La-Serna, Elena, Escudero, Domingo, Llufriu, Sara, Sánchez-Valle, Raquel, Santamaria, Joan, Compte, Albert, Castro-Fornieles, Josefina, Dalmau, Josep, Páramo, Dolores, Medrano, Vicente, Casado, Virginia, Guanyabens, Nicolau, Giné-Servén, Eloi, Ángeles del Real, María, Pardo, Javier, Martin-Gil, Leticia, Barrero-Hernández, Francisco Javier, García-Barragán, Nuria, Falip, Mercè, Simó, Marta, Rodríguez, Eloy, Ruiz Ezquerro, Juan José, Bataller, Luis, Safont, Gemma, Vicente-Hervàs, José, Brieva, Luis, Casado, Ignacio, Portilla, Juan Carlos, Escalante, Sònia, Arenillas, Juan Francisco, Erro, Elena, Jericó-Pascual, Ivonne, Fuerte-Hortigón, Alejandro, Morató, Alba, Saiz, Albert, Blanco, Yolanda, Sepúlveda, Maria, Ruiz, Raquel, Naranjo, Laura, Rodés, Maria, Aguilar, Esther, Alba, Mercè, Caballero, Eva

“…Summary Background Anti-NMDA receptor (NMDAR) encephalitis is associated with a post-acute stage that is not well known. We aimed to describe the clinical…”
Get full text

Diagnosis of HaNDL syndrome by García-Gómez, Francisco Javier, de la Riva-Pérez, Pablo Antonio, Páramo, Dolores, Navarro-Mascarell, Guillermo, Dinca-Avarvarei, Luminita, Calvo-Morón, María de la Cinta

Get full text

Vitíligo con fenómeno de Koebner en una paciente con esclerosis múltiple tratada con alemtuzumab by Eichau Madueño, Sara, López Ruiz, Rocío, Ruiz Peña, Juan Luis, Páramo Camino, Mª Dolores, Navarro Mascarell, Guillermo, Izquierdo Ayuso, Guillermo

Get full text

Immunological markers of optimal response to natalizumab in multiple sclerosis by Villar, Luisa M, García-Sánchez, María I, Costa-Frossard, Lucienne, Espiño, Mercedes, Roldán, Ernesto, Páramo, Dolores, Lucas, Miguel, Izquierdo, Guillermo, Álvarez-Cermeño, José C

“…To explore cell subsets and molecules that changed specifically in patients with multiple sclerosis (MS) who had an optimal response to natalizumab…”
Get more information

Adipose-derived mesenchymal stem cells by Fernández, Oscar, Izquierdo, Guillermo, Fernández, Victoria, Leyva, Laura, Reyes, Virginia, Guerrero, Miguel, León, Antonio, Arnaiz, Carlos, Navarro, Guillermo, Páramo, Maria Dolores, Cuesta, Antonio De la, Soria, Bernat, Hmadcha, Abdelkrim, Pozo, David, Fernandez-Montesinos, Rafael, Leal, Maria, Ochotorena, Itziar, Gálvez, Patricia, Geniz, Maria Angeles, Barón, Francisco Javier, Mata, Rosario, Medina, Cristina, Caparrós-Escudero, Carlos, Cardesa, Ana, Cuende, Natividad

“…Background Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal…”
Get full text

New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab by Toboso, Inmaculada, Tejeda-Velarde, Amalia, Alvarez-Lafuente, Roberto, Arroyo, Rafael, Hegen, Harald, Deisenhammer, Florian, Sainz de la Maza, Susana, Alvarez-Cermeño, José C, Izquierdo, Guillermo, Paramo, Dolores, Oliva, Pedro, Casanova, Bonaventura, Agüera-Morales, Eduardo, Franciotta, Diego, Gastaldi, Matteo, Fernández, Oscar, Urbaneja, Patricia, Garcia-Dominguez, José M, Romero, Fernando, Laroni, Alicia, Uccelli, Antonio, Perez-Sempere, Angel, Saiz, Albert, Blanco, Yolanda, Galimberti, Daniela, Scarpini, Elio, Espejo, Carmen, Montalban, Xavier, Rasche, Ludwig, Paul, Friedemann, González, Inés, Álvarez, Elena, Ramo, Cristina, Caminero, Ana B, Aladro, Yolanda, Calles, Carmen, Eguía, Pablo, Belenguer-Benavides, Antonio, Ramió-Torrentà, Lluis, Quintana, Ester, Martínez-Rodríguez, José E, Oterino, Agustín, López de Silanes, Carlos, Casanova, Luis I, Landete, Lamberto, Frederiksen, Jette, Bsteh, Gabriel, Mulero, Patricia, Comabella, Manuel, Hernández, Miguel A, Espiño, Mercedes, Prieto, José M, Pérez, Domingo, Otano, María, Padilla, Francisco, García-Merino, Juan A, Navarro, Laura, Muriel, Alfonso, Frossard, Lucienne Costa, Villar, Luisa M

“…We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple…”
Get full text

Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab by Eichau, S, Lopez-Ruiz, R, Ruiz-Pena, J L, Paramo, M D, Navarro-Mascarell, G, Izquierdo, G

Get full text

Skin Autoimmunity Secondary to Alemtuzumab in a Tertiary Care Spanish Hospital by Ruiz, Rocío López, Fernández, Félix Sánchez, Ruiz de Arcos, María, García-Soto, Julio Dotor, Hortigón, Alejandro Fuerte, Mascarell, Guillermo Navarro, Ruiz Peña, Juan Luis, Páramo Camino, M Dolores, Guerra Hiraldo, Juan Diego, Eichau, Sara

Get full text

Características clínicas de la enfermedad de Creutzfeldt-Jakob familiar y mutación E200K en España by Morgado Linares, Rosalía Yolanda, Ruiz Peña, Juan Luis, Páramo Camino, Mª Dolores, Díaz Delgado, Mario, Izquierdo Ayuso, Guillermo

Get full text

Eficiencia y relación coste-utilidad del interferón beta en la esclerosis múltiple en Andalucía by Medina Redondo, Felisa, Herrera Carranza, Joaquín, Sanabria, Carmen, Navarro, Guillermo, García Moreno, José Manuel, Gamero García, Miguel Ángel, Páramo Camino, Mª Dolores, Ruiz Peña, Juan Luis, Izquierdo Ayuso, Guillermo

Get full text

Alteraciones neuropsicológicas en la esclerosis lateral amiotrófica. ¿No existen o no se detectan? by Duque San Juan, Pablo, Páramo Camino, Mª Dolores, Borges Guerra, Mónica, Peral Gutiérrez de Ceballos, Enrique, García Moreno, José Manuel, Balarezo Chiriboga, Lucio, Izquierdo Ayuso, Guillermo, Sánchez López, Fernando, Patrignani Ochoa, Jorge H.

Get full text